Novare Capital Management LLC Has $11.28 Million Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Novare Capital Management LLC trimmed its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 3.6% in the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 22,662 shares of the medical research company's stock after selling 853 shares during the quarter. Novare Capital Management LLC's holdings in Thermo Fisher Scientific were worth $11,276,000 as of its most recent filing with the SEC.

A number of other large investors have also bought and sold shares of the business. Bernard Wealth Management Corp. acquired a new position in Thermo Fisher Scientific during the 4th quarter worth approximately $25,000. Pillar Financial Advisors LLC acquired a new position in Thermo Fisher Scientific during the 4th quarter worth approximately $29,000. Ameriflex Group Inc. acquired a new position in Thermo Fisher Scientific during the 4th quarter worth approximately $30,000. Cassady Schiller Wealth Management LLC boosted its holdings in shares of Thermo Fisher Scientific by 89.2% in the 4th quarter. Cassady Schiller Wealth Management LLC now owns 70 shares of the medical research company's stock valued at $36,000 after buying an additional 33 shares during the last quarter. Finally, VSM Wealth Advisory LLC acquired a new stake in shares of Thermo Fisher Scientific in the 4th quarter valued at approximately $36,000. 89.23% of the stock is owned by institutional investors.

Insider Transactions at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $429.93, for a total transaction of $128,979.00. Following the sale, the executive vice president directly owned 23,167 shares of the company's stock, valued at approximately $9,960,188.31. This trade represents a 1.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.33% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

TMO has been the subject of several research reports. The Goldman Sachs Group set a $610.00 price target on Thermo Fisher Scientific and gave the company a "buy" rating in a report on Wednesday, April 23rd. Robert W. Baird lowered their price objective on Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating on the stock in a research report on Thursday, April 24th. Scotiabank lowered their price objective on Thermo Fisher Scientific from $650.00 to $605.00 and set a "sector perform" rating on the stock in a research report on Friday, April 25th. Royal Bank Of Canada lowered their price objective on Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating on the stock in a research report on Thursday, April 24th. Finally, Argus lowered their price objective on Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating on the stock in a research report on Tuesday, April 29th. Four analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat.com, Thermo Fisher Scientific presently has a consensus rating of "Moderate Buy" and an average price target of $604.05.

Thermo Fisher Scientific Price Performance

Thermo Fisher Scientific stock traded up $0.49 during midday trading on Friday, reaching $428.25. The company's stock had a trading volume of 1,359,321 shares, compared to its average volume of 1,974,470. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $627.88. The company has a current ratio of 1.77, a quick ratio of 1.38 and a debt-to-equity ratio of 0.64. The business has a 50-day moving average price of $409.18 and a 200-day moving average price of $479.65. The stock has a market cap of $161.66 billion, a PE ratio of 25.12, a price-to-earnings-growth ratio of 2.28 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.15% and a net margin of 15.19%. The firm had revenue of $10.36 billion for the quarter, compared to analysts' expectations of $10.23 billion. During the same quarter in the previous year, the business posted $5.11 earnings per share. The business's revenue for the quarter was up .2% on a year-over-year basis. On average, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, July 15th. Shareholders of record on Friday, June 13th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 0.40%. The ex-dividend date is Friday, June 13th. Thermo Fisher Scientific's dividend payout ratio is presently 10.09%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.